New drug for hot flashes becomes available nationwide
NEW YORK — Noven Pharmaceuticals has launched a new drug for severe hot flashes nationwide, the company said.
The drug maker announced the availability of Brisdelle (paroxetine) capsules in the 7.5-mg strength, the first-ever non-hormonal drug approved by the Food and Drug Administration for moderate to severe hot flashes associated with menopause.
"The availability of Brisdelle is a major medical advancement for menopausal women dealing with moderate to severe hot flashes, which can often last five years or longer in some women," Northwestern University medical professor Lauren Streicher said in a statement on behalf of Noven. "The reality is, on average, today’s women are living over a third of their lives after the start of menopause. my hope is that this new, clinically proven option will help empower women to initiate a dialogue with their healthcare providers about finding a treatment plan that is right for them."
Retired Nova Scotia pharmacist wins Pfizer Consumer Healthcare Bowl of Hygeia award
NEW YORK — A pharmacist in Canada has won a prestigious award from Pfizer Consumer Healthcare, according to published reports.
Nova Scotia’s Truro Daily News reported that retired pharmacist Allan MacKinnon received the company’s Bowl of Hygeia award during the weekend. Coworkers Kerry Mattatall and Marilyn MacLeod had put together the nomination package for MacKinnon, including 27 letters of support, citing the MacKinnons’ support for their community.
MacKinnon, 65, had worked at the Fulton C G Pharmacy in Tatamagouche, Nova Scotia, since he was 19. He and his wife, Joanne, had started purchasing shares in the pharmacy in 1974 and finished purchasing it in the late 1990s, the newspaper reported, before selling it at the beginning of last year.
Healthcare providers in Asia acknowledge complexity of managing Type 2 diabetes
INDIANAPOLIS — Many physicians in Asia say more information on managing Type 2 diabetes is needed, according to a new poll.
The poll, conducted by Boehringer Ingelheim and Eli Lilly, included 800 doctors from Japan, China, India and South Korea, finding that 79% say the complexity of managing the disease is underestimated. Still, high-qualty, structured patient education can help improve health outcomes for patients with the disease, and 90% said patients and healthcare providers alike would benefit from additional medical information and patient support materials. Additionally, given diabetes patients’ higher risk of cardiovascular disease, 94% of physicians said management of cardiovascular risk influenced their decisions when prescribing oral diabetes drugs.
"More than 60% of the world’s diabetes population lives in Asia, and physicians treating Type 2 diabetes in this region acknowledge that this is a complex condition," Boehringer Ingelheim corporate SVP medicine Klaus Dugi said. "Despite the numerous challenges Type 2 diabetes can present in the face of rising prevalence, results from this survey show that healthcare professionals in Asia are evaluating the full spectrum of available treatments, dosing regimens, risk factors and co-morbidities to achieve the best possible health outcomes for their patients."